Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KRAS G12C + KRAS G12V

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

STK11 deletion + KRAS mutation (6)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

CPS1 overexpression + KRAS mutation + STK11 mutation (3)

HER-2 amplification + KRAS G12D (3)

KEAP1 deletion + KRAS mutation (3)

PD-L1 overexpression + KRAS mutation (3)

EGFR exon 19 deletion + KRAS mutation (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-L/dMMR + KRAS G12V (2)

AXL overexpression + KRAS G12C (1)

CDH2 overexpression + KRAS wild-type (1)

Chr t(11;14) + KRAS mutation (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR expression + KRAS G12C (1)

EGFR overexpression + KRAS 13D (1)

EGFR overexpression + KRAS mutation (1)

FGFR1 overexpression + KRAS G12C (1)

GNA13 deletion + KRAS mutation (1)

GOPC-ROS1 fusion + KRAS Q61H (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 overexpression + KRAS wild-type (1)

IGF1R overexpression + KRAS mutation (1)

IR overexpression + KRAS mutation (1)

IRS2 amplification + KRAS mutation (1)

KEAP1 mutation + KRAS wild-type (1)

KRAS A146 + TMB-H (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS G12D + Chr del(9)(p21) (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS G12D + TP53 deletion (1)

KRAS amplification + BRAF wild-type (1)

KRAS amplification + RAS wild-type (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + BCL2A1 overexpression (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + EGFR amplification (1)

KRAS mutation + ER expression (1)

KRAS mutation + HER-2 positive (1)

KRAS mutation + HR positive (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + PIK3CA wild-type (1)

KRAS mutation + PTPN11 overexpression (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

KRAS mutation + YKL-40 overexpression (1)

KRAS wild-type + BRAF V600E (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

KRAS mutation + STK11 mutation + AXL expression (1)

MLL-AFF1 fusion + KRAS mutation (1)

MSI-H/dMMR + KRAS G12D (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MTAP deletion + KRAS G12C (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

POMK-NRG1 fusion + KRAS mutation (1)

POMK‐NRG1 fusion + KRAS G12D (1)

PTEN deletion + KRAS G12C (1)

RET positive + KRAS G12V (1)

ROS1 fusion + KRAS G12C (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

STRN-ALK fusion + KRAS G13D (1)

TP53 S12F + KRAS G12D + TMB-L (1)

HER-2 amplification + KRAS G12C (0)

PRMT5 overexpression + KRAS mutation (0)

STK11 deletion + KRAS mutation (6)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

CPS1 overexpression + KRAS mutation + STK11 mutation (3)

HER-2 amplification + KRAS G12D (3)

KEAP1 deletion + KRAS mutation (3)

PD-L1 overexpression + KRAS mutation (3)

EGFR exon 19 deletion + KRAS mutation (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-L/dMMR + KRAS G12V (2)

AXL overexpression + KRAS G12C (1)

CDH2 overexpression + KRAS wild-type (1)

Chr t(11;14) + KRAS mutation (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR expression + KRAS G12C (1)

EGFR overexpression + KRAS 13D (1)

EGFR overexpression + KRAS mutation (1)

FGFR1 overexpression + KRAS G12C (1)

GNA13 deletion + KRAS mutation (1)

GOPC-ROS1 fusion + KRAS Q61H (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 overexpression + KRAS wild-type (1)

IGF1R overexpression + KRAS mutation (1)

IR overexpression + KRAS mutation (1)

IRS2 amplification + KRAS mutation (1)

KEAP1 mutation + KRAS wild-type (1)

KRAS A146 + TMB-H (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS G12D + Chr del(9)(p21) (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS G12D + TP53 deletion (1)

KRAS amplification + BRAF wild-type (1)

KRAS amplification + RAS wild-type (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + BCL2A1 overexpression (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + EGFR amplification (1)

KRAS mutation + ER expression (1)

KRAS mutation + HER-2 positive (1)

KRAS mutation + HR positive (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + PIK3CA wild-type (1)

KRAS mutation + PTPN11 overexpression (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

KRAS mutation + YKL-40 overexpression (1)

KRAS wild-type + BRAF V600E (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

KRAS mutation + STK11 mutation + AXL expression (1)

MLL-AFF1 fusion + KRAS mutation (1)

MSI-H/dMMR + KRAS G12D (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MTAP deletion + KRAS G12C (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

POMK-NRG1 fusion + KRAS mutation (1)

POMK‐NRG1 fusion + KRAS G12D (1)

PTEN deletion + KRAS G12C (1)

RET positive + KRAS G12V (1)

ROS1 fusion + KRAS G12C (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

STRN-ALK fusion + KRAS G13D (1)

TP53 S12F + KRAS G12D + TMB-L (1)

HER-2 amplification + KRAS G12C (0)

PRMT5 overexpression + KRAS mutation (0)

›

1year

Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC). (ASCO-GI 2024)

A Cox Proportional Hazard analysis of OS across all patients found that Gemcitabine and Gemcitabine with Nabpaclitaxel had significantly higher HR than FOLFIRINOX... Our data suggest that FOLFIRINOX has a longer TTNT than other first-line regimens for KRAS G12C, G12V, G12D, and G12R. KRAS G12C was associated with the shortest OS among common KRAS mutations. >

1 year ago

Clinical • Metastases

|

KRAS (KRAS proto-oncogene GTPase)

|

KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS G13 • KRAS G12C + KRAS G12V

|

gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium

over1year

RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts (ESMO-GI 2023)

In this cohort with population-based and real-world patients, no differences in patient characteristics or treatment modalities were seen between different RAS mt, except a higher frequency of right-colon primaries among KRAS mt compared with NRAS mt. KRAS -G12S conferred a worse OS compared with some other KRAS mt, whereas no other differences in OS were seen. It therefore seems as if different RAS mt behave quite similar.

over 1 year ago

Clinical • Metastases

|

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)

|

BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • KRAS G12D • KRAS G12V • RAS mutation • NRAS Q61K • KRAS G12A • KRAS G12 • NRAS Q61 • KRAS G12S • NRAS Q61R • KRAS G13 • KRAS Q61H • NRAS G12D • NRAS G12 • NRAS G13 • KRAS A146T • NRAS A146T • NRAS A146 • KRAS G12C + KRAS G12V • KRAS Q61K • NRAS G12S

almost2years

Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer (AACR 2023)

The combination of avutometinib and everolimus overcomes the activation of the PI3K/AKT/mTOR pathway which is an adaptive resistance mechanism to MAPK pathway inhibition. We have shown that avutometinib and everolimus induce synergistic anti-tumor effects preclinically, and preliminary data suggest clinically meaningful ORR and PFS in patients with KRAS mt NSCLC including non-G12C variants.

almost 2 years ago

Preclinical • Combination therapy

|

KRAS (KRAS proto-oncogene GTPase) • RPS6 (Ribosomal Protein S6) • AKT1S1 (AKT1 Substrate 1)

|

KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS Q61H • KRAS G13A • KRAS G12C + KRAS G12V

|

everolimus • avutometinib (VS-6766)